Obamacare Repeal Failure and Cancer Research Developments
In this week’s BioBlog we look at the failure of the senate to pass a healthcare bill to repeal Obamacare and what it means for insurers and the market. We also look at new developments in cancer research in cancer gene mapping and stem cell therapy.
A vote early Friday morning in the senate ended with the fight to repeal Obamacare failing to pass. What does this mean for the future of Obamacare and the individual marketplace?
After the defeat the healthcare bill in the senate, President Trump is threatening to stop the payments that insurance companies receive under Obamacare, unless congress acts quickly and passes a repeal and replace bill.
With the failure of the healthcare bill in the senate, insurance companies have been left in limbo with many questions they need answers to in order to prepare and plan for 2018.
Cancer researchers in the US have completed a map of genes that cancer tumors rely on. This will offer new options for targeted treatments.
A new stem cell based treatment has been shown to kill breast cancer cells in mice. If it works in humans it may also be able to reduce the side effects of chemotherapy.